These years, several immune checkpoints including CTLA-4 and PD-1/PD-L1 were identified and multiple agents have been developed to bind with the immunologic checkpoints and block checkpoint-pathways, which would otherwise impair the T cell anti-tumor activity. This evidence concerns the gene CD274 and neoplasm.